SYNGENSYS

Startup

SynGenSys designs synthetic mammalian gene promoters and signal peptides that outperform traditional systems and give biologics developers choice and control over how much protein is expressed, and where. For biopharmaceutical manufacturing, the market-ready CHO.SET® promoter library delivers higher productivity per cell than the industry-standard CMV promoter across GS-KO CHO platforms, even for difficult-to-express proteins. Higher productivity per cell opens the door to smaller batch sizes, lower cost of goods and shorter timelines to toxicity studies. The promoters are ready to license and drop into existing CHO workflows, with bespoke design available for HEK and other host systems.

The company's proprietary informatics and computational design platform maps the transcriptional landscape of a target cell type or tissue, identifies the regulatory features driving on-target and off-target expression, and builds compact synthetic sequences engineered for that specific application.

For cell and gene therapy, SynGenSys offers synthetic promoter sets for a range of applications and customer requirements, sized to fit the payload constraints of AAV and other delivery vectors, and tuned for the strength and specificity a therapy requires. Where an off-the-shelf set is not the right fit, the computational platform supports fully bespoke promoter design. SynGenSys also supplies signal peptides, including a set optimised for efficient expression and translocation of chimeric antigen receptors (CARs).